[Efficacy of a daily application of mesalazine (Pentasa) suppository with progressive release, in the treatment of ulcerative proctitis. A double-blind versus placebo randomized trial].

Abstract

Therapeutic efficacy of mesalazine controlled-release suppository 1 g once daily was compared with that of a placebo during 2 weeks in 50 patients (26 in the mesalazine group, 24 in the placebo group) with ulcerative proctitis, in a double-blind randomized trial. Endoscopic and clinical remission was seen in 69 and 65% of mesalazine-treated patients and in 33 and 25% of placebo-treated patients respectively (P < or = 0.01). No side effects were seen. It is concluded that a once-a-day administration of 1 g mesalazine controlled-release suppository is effective for topical treatment of patients with ulcerative proctitis.

• Authors: Y Ngô, J M Gélinet, A Ivanovic, J Kac, G Schénowitz, J Vilotte, J C Rambaud
• Journal: Gastroenterologie clinique et biologique (Gastroenterol Clin Biol) Vol. 16 Issue 10 Pg. 782-6 ( 1992) ISSN: 0399-8320 [Print] France
• Vernacular Title: Efficacité d'une application quotidienne d'un suppositoire de mésalazine (Pentasa) à libération progressive, dans le traitement des poussées de rectite ulcéro-hémorragique. Essai randomisé en double aveugle contre placebo.
• PMID: 1478406 (Publication Type: Clinical Trial, English Abstract, Journal Article, Randomized Controlled Trial)

Chemical References

• Aminosalicylic Acids
• Placebos
• Suppositories
• Mesalamine

Topics

• Adult
• Aged
• Aged, 80 and over
• Aminosalicylic Acids (administration & dosage)
• Colitis, Ulcerative (drug therapy, pathology)
• Dose-Response Relationship, Drug
• Double-Blind Method
• Female
• Humans
• Male
• Mesalamine
• Middle Aged
• Placebos
• Suppositories